ICONOVO.SE
Company in Sweden
Resume
Iconovo offers the development of inhalation products, inhaler devices and dry powder formulation, and characterization of the final product.
Video Presentation
Finance
| Finance | Annual Report
Latest
Iconovo receives positive guidance from FDA regarding substitutability for ICOpre
September 20, 2024
Iconovo announces that the US Food and Drug Administration (FDA) has issued a positive guidance regarding the generic substitutability of the company’s proprietary inhaler ICOpre® with the original drug Breo Ellipta with respect to external design and operating principles.
The FDA’s preliminary view is that ICOpre with its current external design attributes and operating principle […] The post Iconovo receives positive guidance from FDA regarding substitutability for ICOpre appeared first on Iconovo.
September 20, 2024
Iconovo announces that the US Food and Drug Administration (FDA) has issued a positive guidance regarding the generic substitutability of the company’s proprietary inhaler ICOpre® with the original drug Breo Ellipta with respect to external design and operating principles.
The FDA’s preliminary view is that ICOpre with its current external design attributes and operating principle […] The post Iconovo receives positive guidance from FDA regarding substitutability for ICOpre appeared first on Iconovo.
Profile last updated on October 4th, 2024